Literature DB >> 16364714

Contralateral cervical and mediastinal lymph node metastasis in medullary thyroid cancer: systemic disease?

Andreas Machens1, Hans-Jürgen Holzhausen, Henning Dralle.   

Abstract

BACKGROUND: The current American Joint Committee on Cancer/International Union Against Cancer classification designates cervical and mediastinal lymph nodes as regional lymph nodes. In a unilateral thyroid neoplasm, however, involvement of the contralateral cervical lymph node compartment or the mediastinal lymph node compartment, both of which have been designated "distant" lymph nodes, may serve as a surrogate parameter of distant metastases.
METHODS: This institutional series consisted of 105 consecutive patients with medullary thyroid cancer who underwent systematic dissections of both distant lymph node compartments.
RESULTS: Thirty-eight patients had no distant lymph node metastasis, 36 patients had involvement of only 1, and 31 patients of both distant lymph node compartments. Significant associations (P < .001) were seen on univariate analysis between the number of involved "distant" lymph node compartments (none, one, or both) and extrathyroidal extension (3%, 33%, and 58%), the number of positive lymph nodes (means of 3, 13, and 33), and distant metastasis (8%, 36%, and 61%). In a multivariate logistic regression model, only involvement of one or both "distant" lymph node compartments (versus no distant lymph node metastasis) remained significantly related to distant metastasis in a dose-dependent fashion.
CONCLUSIONS: "Distant" lymph nodes in medullary thyroid cancer should be regarded as nonregional lymph nodes because their involvement is indicative of distant metastasis.

Entities:  

Mesh:

Year:  2006        PMID: 16364714     DOI: 10.1016/j.surg.2005.06.018

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  9 in total

Review 1.  Medullary thyroid cancer: monitoring and therapy.

Authors:  Douglas W Ball
Journal:  Endocrinol Metab Clin North Am       Date:  2007-09       Impact factor: 4.741

2.  Treating medullary thyroid cancer in the age of targeted therapy.

Authors:  Maria E Cabanillas; Mimi I Hu; Camilo Jimenez; Elizabeth G Grubbs; Gilbert J Cote
Journal:  Int J Endocr Oncol       Date:  2014

Review 3.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

4.  Tumor protein p53-induced nuclear protein (TP53INP1) expression in medullary thyroid carcinoma: a molecular guide to the optimal extent of surgery?

Authors:  D Taïeb; S Giusiano; F Sebag; M Marcy; C de Micco; F F Palazzo; N J Dusetti; J L Iovanna; J F Henry; S Garcia; Colette Taranger-Charpin
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

5.  [Lymphadenectomy for thyroid and lymph node carcinomas].

Authors:  O Gimm; H Dralle
Journal:  Chirurg       Date:  2007-03       Impact factor: 0.955

Review 6.  [Hereditary thyroid cancer].

Authors:  H Dralle; A Machens; K Lorenz
Journal:  Chirurg       Date:  2008-11       Impact factor: 0.955

7.  [Surgery of thyroid carcinoma].

Authors:  H Dralle; K Lorenz; A Machens
Journal:  Chirurg       Date:  2009-11       Impact factor: 0.955

8.  Analysis of risk factors for cervical lymph node metastases in patients with sporadic medullary thyroid carcinoma.

Authors:  Weina Fan; Cheng Xiao; Fusheng Wu
Journal:  J Int Med Res       Date:  2018-03-23       Impact factor: 1.671

9.  Extent of surgery in clinically evident but operable MTC - when is central and/or lateral lympadenectomy indicated?

Authors:  Oliver Gimm
Journal:  Thyroid Res       Date:  2013-03-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.